CA Patent

CA3184218A1 — Aryl phosphorus oxide compounds and use thereof

Assigned to CHENGDU DI'AO JIUHONG PHARMACEUTICAL FACTORY · Expires 2022-01-06 · 4y expired

What this patent protects

The present invention provides arylphosphine oxide compounds with kinase inhibitory activity. The compounds can effectively inhibit the activity of various types of EGFR drug-resistant mutants (e.g., EGFRdel19, EGFRdel19/T790M, EGFRdel19/C797S, EGFRT790M/L858R, EGFRL858R/C797S, E…

USPTO Abstract

The present invention provides arylphosphine oxide compounds with kinase inhibitory activity. The compounds can effectively inhibit the activity of various types of EGFR drug-resistant mutants (e.g., EGFRdel19, EGFRdel19/T790M, EGFRdel19/C797S, EGFRT790M/L858R, EGFRL858R/C797S, EGFRdel19/T790M/C797S, and EGFRL858R/T790M/C797S), and also have significant inhibition of ALK fusion genes and mutants (e.g., L1196M), and thus can be used for treatment, combined therapy or prevention of various types of cancers.

Drugs covered by this patent

Patent Metadata

Patent number
CA3184218A1
Jurisdiction
CA
Classification
—
Expires
2022-01-06
Drug substance claim
No
Drug product claim
No
Assignee
CHENGDU DI'AO JIUHONG PHARMACEUTICAL FACTORY
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.